triumph-1 retatrutide trial results: Retatrutide, the triple agonist. Significant weight loss ( 28.3% average loss at 80 weeks). It has potential to transform obesity treatment with results comparable to… 🚨 Retatrutide TRIUMPH-1 Phase 3

Understanding the distinction between true dermal thinning and the appearance of skin changes secondary to fat loss is essential for appropriate management

The behavior change app will be available to eligible members as part of the CareFirst WellBeing Program

In this retrospective cohort study, adults (1889 years) undergoing outpatient esophagogastroduodenoscopy or colonoscopy within the HCA Healthcare network from 1 July 2021 to 31 March 2024 were identified

Ethics declarations Ethics approval and consent to participate The current study was approved by the Research Ethics Committee of Isfahan University of Medical Sciences (ID: IR.MUI.RESEARCH.REC.1400.037, March 2021)